TiGenix Potential Therapy for Crohn’s-related Perianal Fistulas Gets FDA Approval

TiGenix Potential Therapy for Crohn’s-related Perianal Fistulas Gets FDA Approval
The U.S. Food and Drug Administration (FDA) has granted TiGenix orphan drug designation for its lead candidate Cx601, which aims to treat perianal fistulas caused by Crohn’s disease in patients who have not improved with conventional treatments. About 10 to 15 percent of Crohn’s patients develop such fistulas. These are small abnormally formed channels that connect the area close to the anus and the outside skin area, causing constant, throbbing pain. Current treatments for this secondary manifestation of Crohn’s include antibiotics, immunosuppressants, anti-TNFs and surgery. However, none produce long-lasting benefits, and all have potentially severe complications and safety concerns
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *